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ABSTRACT
Objectives Type 2 myocardial infarction (MI) is 
a heterogenous condition and whether there are 
differences between women and men is unknown. 
We evaluated sex differences in clinical characteristics, 
investigations and outcomes in patients with type 2 MI.
Methods In the Swedish Web based system for 
Enhancement and Development of Evidence based care 
in Heart disease Evaluated According to Recommended 
Therapies (SWEDEHEART) registry, we compared patients 
admitted to coronary care units with a diagnosis of type 
1 or type 2 MI. Sex- stratified Cox regression models 
evaluated the association with all- cause death in men 
and women separately.
Results We included 57 264 (median age 73 years, 
65% men) and 6485 (median age 78 years, 50% men) 
patients with type 1 and type 2 MI, respectively. No 
differences were observed in the proportion of men and 
women with type 2 MI who underwent echocardiography 
and coronary angiography, but women were less likely 
than men to have left ventricular (LV) impairment and 
obstructive coronary artery disease (CAD). Compared 
with type 1 MI, patients with type 2 MI had higher risk of 
death regardless of sex (men: adjusted HR 1.55 (95% CI 
1.44 to 1.67); women: adjusted HR 1.34 (95% CI 1.24 
to 1.45)). In those with type 2 MI, the risk of death was 
lower for women than men (adjusted HR 0.85 (95% CI 
0.76 to 0.92) (men, reference)).
Conclusions Type 2 MI occurred in men and women 
equally and we found no evidence of sex bias in the 
selection of patients for cardiac investigations. Patients 
with type 2 MI had worse outcomes, but women 
were less likely to have obstructive CAD or severe LV 
impairment and were more likely to survive than men.
INTRODUCTION
Patients with type 2 myocardial infarction (MI) 
have a poor prognosis,1 2 and this condition is a 
heterogeneous entity with multiple aetiologies and 
triggers.3 Insights into the patient groups who are at 
highest risk and the clinical features that influence 
outcomes are required to develop evidence- based 
treatments that reduce mortality.
It has been observed that the majority of patients 
diagnosed with type 1 MI are men. Intriguingly, 
recent studies have suggested that the proportion of 
patients with type 2 MI who are women is higher.4–7 
Similarly, the investigation and treatment of type 
1 MI differs in men and women, with women 
less likely to receive evidence- based therapies.8–10 
Whether the clinical characteristics and investiga-
tions differ in men and women with type 2 MI, and 
how these impact on outcomes is not known.
Here, we compare the clinical characteristics, 
investigations and outcomes of consecutive patients 
with type 1 and type 2 MI stratified by sex. Our 
aim was to define the predictors of death and major 
adverse cardiovascular events (MACE) in patients 
with a diagnosis of type 2 MI, and to determine 
whether these differ in men and women.
METHODS
Study population
Patients were enrolled in the Swedish Web based system 
for Enhancement and Development of Evidence 
based care in Heart disease Evaluated According to 
Recommended Therapies (SWEDEHEART) registry 
between September 2010 and May 2018. The ratio-
nale and methods for data collection have been 
described previously.11 The SWEDEHEART registry 
includes consecutive patients admitted to coronary 
care units (CCU) or other specialised facilities at all 
Swedish hospitals. To ensure the correctness and 
quality of the data entered, hospitals are monitored 
on a regular basis.11 Patients included in the registry 
are informed about their participation which they 
have the right to decline. Written consent is not 
required according to Swedish law.
For this study, we included all unique patients with 
a diagnosis of type 1 or type 2 MI according to the 
treating physician based on the criteria outlined in 
the Universal Definition of Myocardial Infarction.12 
To standardise the study cohort, we included only 
patients with available maximum results for high- 
sensitivity cardiac troponin T (hs- cTnT), and did not 
consider patients assessed at sites using other cardiac 
troponin assays. Similarly, we did not consider 
patients with ST- elevation MI (STEMI) in the 
primary analysis as care pathways for this condition 
are highly standardised and the majority of patients 
have type 1 MI. Patients with STEMI were, however, 
included in a secondary analysis to verify the robust-
ness of our findings across all patients with MI. The 
present manuscript follows the Strengthening the 
Reporting of Observational Studies in Epidemiology 
guidelines.13
Patient and public involvement
This research was done without patient involvement.
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Clinical outcomes
We used the Swedish Patient Registry (hospitalisation dates and 
discharge diagnoses based on International Classification of 
Diseases, 10th revision (ICD-10) codes) and the Swedish Popu-
lation Registry to obtain clinical outcomes. The accuracy of 
hospital discharge diagnosis codes in this registry has previously 
been evaluated showing 85% to 95% validity.14 We investigated 
the occurrence of all- cause death and MACE until May 2018 and 
December 2017 respectively. MACE was defined as a composite 
end point of all- cause mortality, readmissions for non- fatal MI 
Table 1 Clinical characteristics of patients with type 1 myocardial infarction and type 2 myocardial infarction, stratified by sex
Clinical characteristics*














  Age (years) 73 (64–81) 71 (62–79) 77 (68–84) 78 (70–85) 77 (69–84) 80 (71–86)
  Body mass index (kg/m2) 26.6 (24.1–29.7) 26.8 (24.5–29.7) 26.2 (23.1–29.8) 25.6 (22.9–29.1) 25.9 (23.5–28.7) 25.4 (22.3–29.3)
Risk factors
  Current smoking 9636 (18%) 6528 (18%) 3108 (17%) 809 (14%) 410 (15%) 399 (14%)
  Hypertension 33 313 (59%) 20 592 (55%) 12 721 (64%) 4015 (62%) 1977 (62%) 2038 (63%)
  Diabetes 15 152 (27%) 9717 (26%) 5435 (27%) 1889 (29%) 1056 (33%) 833 (26%)
  Hyperlipidaemia 22 520 (40%) 15 189 (41%) 7331 (37%) 2892 (45%) 1636 (51%) 1256 (39%)
  eGFR (CKD- EPI, mL/kg/m2) 73 (52–88) 75 (56–90) 66 (47–84) 57 (37–79) 57 (36–78) 58 (38–79)
Medical history
  Previous myocardial infarction 18 868 (33%) 12 555 (34%) 6313 (32%) 2553 (40%) 1437 (45%) 1116 (35%)
  Previous CABG 7155 (13%) 5399 (15%) 1756 (9%) 989 (15%) 675 (21%) 314 (10%)
  Previous PCI 12 711 (22%) 8996 (24%) 3715 (19%) 1279 (20%) 804 (25%) 475 (15%)
  Heart failure 7014 (13%) 4632 (13%) 2382 (12%) 1282 (21%) 764 (25%) 518 (17%)
  Previous stroke 5401 (10%) 3416 (9%) 1985 (10%) 870 (14%) 490 (15%) 380 (12%)
  COPD 4833 (8%) 2716 (7%) 2117 (11%) 1158 (18%) 527 (16%) 631 (19%)
  Dementia 440 (1%) 251 (1%) 189 (1%) 80 (1%) 36 (1%) 44 (1%)
  Previous or present cancer 2410 (4%) 1779 (5%) 631 (3%) 497 (8%) 351 (11%) 146 (5%)
ECG findings
  Heart rhythm
   Sinus rhythm 49 574 (87%) 32 382 (87%) 17 192 (87%) 4354 (68%) 2075 (65%) 2279 (71%)
   Atrial fibrillation/flutter 5798 (10%) 3691 (10%) 2107 (11%) 1756 (27%) 909 (28%) 847 (26%)
   Other 1512 (3%) 1057 (3%) 455 (2%) 322 (5%) 218 (7%) 104 (3%)
  Ischaemic findings
   ST- segment depression 17 773 (31%) 11 373 (31%) 6400 (33%) 2211 (35%) 1148 (36%) 1063 (33%)
   T- wave inversion 7507 (13%) 4723 (13%) 2784 (14%) 637 (10%) 285 (9%) 352 (11%)
   Other ST- segment changes 12 832 (23%) 8299 (22%) 4533 (23%) 1725 (27%) 928 (30%) 797 (25%)
   No ST- segment changes 18 489 (33%) 12 567 (34%) 5922 (30%) 1768 (28%) 799 (25%) 969 (31%)
In- hospital examinations and intervention
  Echocardiography 44 668 (78%) 29 877 (80%) 14 791 (75%) 4201 (65%) 2103 (65%) 2098 (65%)
  Coronary angiography 45 229 (79%) 31 184 (83%) 14 045 (71%) 2272 (35%) 1150 (36%) 1122 (35%)
  PCI 33 083 (58%) 23 592 (63%) 9491 (48%) 734 (11%) 463 (14%) 271 (8%)
  CABG 4069 (7%) 3163 (9%) 906 (5%) 76 (1%) 63 (2%) 13 (0%)
Angiographic findings
  Inconclusive 79 (0%) 48 (0%) 31 (0%) 3 (0%) 2 (0%) 1 (0%)
  Normal or non- occlusive disease 4562 (11%) 1942 (7%) 2620 (19%) 1138 (50%) 385 (33%) 753 (66%)
  1- vessel to 2- vessel obstructive disease 25 024 (57%) 17 465 (58%) 7559 (56%) 656 (28%) 392 (34%) 264 (23%)
  3- vessel obstructive disease/left main stem 13 858 (32%) 10 412 (35%) 3446 (25%) 499 (22%) 376 (33%) 123 (11%)
Left ventricular ejection fraction
  ≥50% 28 938 (65%) 19 341 (65%) 9597 (65%) 2319 (56%) 1056 (51%) 1263 (61%)
  31%–49% 13 158 (30%) 8762 (29%) 4396 (30%) 1483 (35%) 805 (38%) 678 (32%)
  ≤30% 2361 (5%) 1633 (6%) 728 (5%) 376 (9%) 229 (11%) 147 (7%)
Medication at discharge
  Aspirin 51 547 (91%) 34 126 (92.4%) 17 421 (89.1%) 4135 (65%) 2110 (67%) 2025 (64%)
  P2Y12 inhibitors 45 751 (81%) 30 334 (82%) 15 417 (79%) 2305 (36%) 1260 (40%) 1045 (33%)
  Anticoagulants 5319 (9%) 3481 (9%) 1838 (9%) 1186 (19%) 583 (18%) 603 (19%)
  Βeta- blockers 48 851 (87%) 32 022 (87%) 16 829 (86%) 5056 (80%) 2555 (81%) 2501 (78%)
  ACEI 30 450 (54%) 21 061 (57%) 9389 (48%) 2628 (41%) 1401 (44%) 1227 (38%)
  ARB 13 106 (23%) 7995 (22%) 5111 (26%) 1419 (22%) 645 (20%) 774 (24%)
  Statins 49 947 (88%) 33 811 (92%) 16 136 (83%) 4084 (64%) 2206 (70%) 1878 (59%)
hs- cTnT (ng/L) 269 (100–782) 280 (100–843) 250 (98–684) 272 (115–666) 298 (121–804) 246 (107–570)
Duration of hospital stays (days) 4 (3–6) 4 (3–7) 4 (3–7) 5 (3–8) 5 (3–8) 5 (3–8)
Continuous data are presented as mean (SD) or mean (IQR), as appropriate. Categorical data are presented as n (%).
*The number (%) of missing values of clinical characteristics are presented in online supplemental table 1.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass graft; CKD- EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; 
hs- cTnT, high- sensitivity cardiac troponin T; PCI, percutaneous coronary intervention.
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(I21), heart failure (I50) and ischaemic stroke (I63). During the 
first 30 days after the index hospitalisation, it was not possible 
to separate a new MI from an index MI, and therefore only MI 
occurring 30 days after the index hospitalisation was included.
Statistical analysis
Comparisons were made between men and women, and between 
those with type 1 and type 2 MI. Sex- specific incidence rates 
were determined and Kaplan- Meier curves were constructed 
to investigate the occurrence of all- cause death and MACE over 
time. Univariable and multivariable cox regression analyses were 
performed to investigate differences between groups (type 1 
MI=reference; men=reference) on clinical outcomes using three 
models with sequential adjustment of covariates. Model 1 presents 
the univariable model (model 1: crude model+hospital site, admis-
sion year). We were interested whether the differences would be 
attenuated when we adjusted for comorbidities, which is presented 
in model 2 (model 2: model 1+adjusted for age, current smoking, 
hypertension, diabetes, hyperlipidaemia, coronary artery disease 
(CAD, defined as previous MI or coronary revascularisation 
procedure), congestive heart failure, previous stroke, ST- segment 
depression, estimated glomerular filtration rate (eGFR), chronic 
obstructive pulmonary disease (COPD), dementia, previous or 
present cancer). Model 3 was additionally adjusted for hs- cTnT 
concentrations since sex- specific variations in the extent of 
myocardial damage potentially might have affected our findings 
(model 3: model 2+hs- cTnT concentrations). To obtain a normal 
distribution, we naturally log transformed eGFR and hs- cTnT 
before they entered the model. To investigate the relationship 
between clinical characteristics and outcomes in men and women 
with type 2 MI, we conducted multivariable Cox regression anal-
ysis. We tested for interactions between these variables and sex 
and a p value <0.1 was considered to be statistically significant. 
Due to the low proportion of missing values of variables (online 
supplemental table 1), no imputation techniques were conducted. 
In secondary analyses, we (1) included patients with STEMI and 
(2) included only patients who underwent coronary angiography 
(CAG), and we adjusted additionally for the extent of CAD (cate-
gorised as normal or non- occlusive disease (reference), 1- vessel to 
2- vessel obstructive disease, 3- vessel obstructive disease/left main 
stem and inconclusive findings). Statistical analysis was done by 
SPSS V.26.0 (IBM).
RESULTS
After excluding patients with a diagnosis other than type 1 or 
type 2 MI and those without hs- cTnT results, 63 749 hospital 
admissions were included in our study (online supplemental 
figure 1). Of these, 57 264 and 6485 were diagnosed with type 1 
and type 2 MI, respectively. More men than women were diag-
nosed with type 1 MI (37 397/57 264 (65%) vs 19 867/57 264 
(35%)), whereas the proportion of men and women with type 2 
MI was the same (3232/6485 (50%) vs 3253/6485 (50%)).
Clinical characteristics
Patients with type 2 MI were older and had a lower eGFR 
compared with those with type 1 MI, but they had a similar 
prevalence of risk factors and comorbidities (table 1). Men with 
type 2 MI were on average 3 years younger than women. They 
were more likely to have diabetes mellitus and hyperlipidaemia. 
Men more often had a prior history of MI, coronary revascu-
larisation and heart failure. Peak hs- cTnT levels were higher for 
men than women.
In-hospital investigations
Patients with type 2 MI were less likely than those with type 1 MI to 
undergo echocardiography, CAG or revascularisation. In patients 
with type 2 MI, no difference was observed in the proportion of 
men and women who underwent echocardiography. However, in 
those who were scanned, a normal ejection fraction was observed 
less often in men than women (51% vs 61%). Likewise, a similar 
proportion of men and women with type 2 MI underwent CAG. 
Women were twice as likely to have normal coronary arteries 
or non- obstructive cardiac disease than men (66% vs 33%), and 
therefore were less likely to undergo coronary revascularisation 
(9% vs 16%). Prescription of medications at discharge tended to 
Figure 1 Crude cumulative occurrence of all- cause death in patients 
with type 1 and type 2 myocardial infarction (MI), stratified by sex.
Figure 2 Crude cumulative occurrence of major adverse 
cardiovascular events (MACE) in patients with type 1 and type 2 
myocardial infarction (MI), stratified by sex. MACE is defined as a 
composite end point of all- cause mortality, readmissions for non- fatal 
MI, heart failure and ischaemic stroke.
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be higher for men than women, particularly the prescription of 
statins was higher in men. In an exploratory analysis, we observed 
no association with female sex and the prescription of statins when 
accounting for comorbidities and angiographic findings (adjusted 
OR 0.84 (95% CI 0.67 to 1.05)).
Clinical outcomes
A total of 56 017 unique patients were identified of whom 50 575 
and 5442 had a diagnosis of type 1 and type 2 MI, respectively 
(online supplemental figure S1). These patients were included in 
the prognostic analyses (figures 1 and 2). For all- cause death, the 
median follow- up was 2.8 (1.2–4.8) and 2.6 (1.0–4.6) years for 
men and women, respectively. For MACE, the median follow- up 
was 2.1 (0.7–4.1) and 1.9 (0.5–3.8) years for men and women, 
respectively. During follow- up, 22% (7147/33 317) of men and 
29% (5064/17 238) of women with type 1 MI died, compared 
with 50% (1334/2668) of men and 45% (1245/2774) of women 
with type 2 MI (table 2). MACE occurred in 30% (9655/31 
977) of men and 39% (6419/16 628) of women with type 1 MI, 
compared with 58% (1490/2559) of men and 53% (1435/2,685) 
of women with type 2 MI.
We compared the crude risk of all- cause death and MACE 
between patients with type 1 and type 2 MI; men with type 2 MI 
were at highest risk, while men with type 1 MI were at lowest risk 
for both outcomes. For both men and women with type 2 MI, the 
crude risk of death was higher compared with type 1 MI. These 
differences were attenuated but remained significant after adjust-
ment for risk factors and comorbidities (men: HR 1.54 (95% CI 
1.43 to 1.65); women: HR 1.32 (95% CI 1.23 to 1.43), table 3). 
Similarly, in patients with type 2 MI, the crude risk of MACE 
compared with those with type 1 MI was also higher for both men 
and women, and was attenuated after adjustment but remained 
significant (men: HR 1.35 (95% CI 1.26 to 1.44); women: HR 
1.25 (95% CI 1.17 to 1.35)).
In type 2 MI, a higher incidence rate of all- cause death and 
MACE was observed in men as compared with women (figure 3). 
Even after adjustment for risk factors and comorbidities, women 
were more likely to survive than men (HR 0.81 (95% CI 0.74 
to 0.90), table 4). Differences in the risk of MACE between men 
and women were attenuated after adjustment for risk factors and 
comorbidities. Additional adjustment for coronary revascularisa-
tion and discharge medications in an explorative analysis yielded 
similar results (all- cause death: HR 0.82 (95% CI 0.74 to 0.91); 
MACE: HR 0.92 (95% CI0.84 to 1.01)).
We investigated the associations between clinical characteris-
tics and outcomes in women and men with type 2 MI (table 5). A 
significant interaction for all- cause death was observed between 
sex and the risk factors of previous history of ischaemic stroke, 
previous history of CAD, hyperlipidaemia and hs- cTnT levels, 
and these risk factors seem more strongly associated with all- 
cause death in women than in men. For MACE, a significant 
interaction with sex was observed for hyperlipidaemia and the 
previous history of CAD with a stronger relative importance of 
these conditions in women (online supplemental table S2).
Secondary analyses
We conducted secondary analyses by including patients with 
STEMI, and adjusting for the extent of CAD in the regression 
model. We observed that the results did not alter. When we 
included patients with STEMI in our analysis, both men and 
women with type 2 MI had a worse prognosis compared with 
patients with type 1 MI (online supplemental table S3). Also 
men with type 2 MI remained at increased risk of all- cause 
death compared with women with type 2 MI (online supple-
mental table S4). Our results also did not change when we 
adjusted for the extent of CAD (online supplemental tables 
S5- S6).
Table 2 Incidence of all- cause death and major adverse events in women and men with type 2 or type 1 myocardial infarction
Men (n=35 985) Women (n=20 032)
N (%) Incidence rate N (%) Incidence rate
Type 1 myocardial infarction*   
  All- cause death 7147/33 317 (22%) 69/1000 person- years 5064/17 258 (29%) 99/1000 person- years
  Major adverse cardiovascular events 9655/31 977 (30%) 116/1000 person- years 6419/16 628 (39%) 160/1000 person- years
Type 2 myocardial infarction†   
  All- cause death 1334/2668 (50%) 215/1000 person- years 1245/2774 (45%) 183/1000 person- years
  Major adverse cardiovascular events 1490/2559 (58%) 316/1000 person- years 1435/2685 (53%) 275/1000 person- years
*Type 1 myocardial infarction no follow- up data available for major adverse cardiovascular events, n=1970 (3.9%).
†Type 2 myocardial infarction no follow- up data available for major adverse cardiovascular events, n=198 (3.6%).
Table 3 Risk of all- cause death and major adverse cardiovascular events for patients with type 2 MI compared with type 1 MI stratified by sex
Total Men Women
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
All- cause death* (type 1 MI, ref cat)
  Model 1 (crude) 2.32 (2.20 to 2.44) <0.001 3.06 (2.85 to 3.28) <0.001 1.77 (1.64 to 1.91) <0.001
  Model 2 (model 1+adjusted for comorbidities) 1.44 (1.36 to 1.51) <0.001 1.54 (1.43 to 1.65) <0.001 1.32 (1.23 to 1.43) <0.001
  Model 3 (model 2+adjusted for hs- cTnT concentrations) 1.45 (1.38 to 1.53) <0.001 1.55 (1.44 to 1.67) <0.001 1.34 (1.24 to 1.45) <0.001
Major adverse cardiovascular events† (type 1 MI, ref cat)
  Model 1 (crude) 2.00 (1.91 to 2.10) <0.001 2.49 (2.34 to 2.66) <0.001 1.62 (1.51 to 1.73) <0.001
  Model 2 (model 1+adjusted for comorbidities) 1.30 (1.24 to 1.36) <0.001 1.34 (1.25 to 1.43) <0.001 1.24 (1.16 to 1.33) <0.001
  Model 3 (model 2+adjusted for hs- cTnT concentrations) 1.31 (1.25 to 1.37) <0.001 1.35 (1.26 to 1.44) <0.001 1.25 (1.17 to 1.35) <0.001
Model 1: MI type, sex, hospital site, year; model 2: model 1+age, current smoking, hypertension, diabetes, hyperlipidaemia, coronary artery disease, congestive heart failure, previous stroke, ST- segment depression, estimated glomerular filtration 
rate, COPD, dementia, previous or present cancer; model 3: model 2+hs- cTnT levels. In sex- stratified analysis, sex is not included in the models.
*Total, n=47 760; women, n=16 664; men, n=31 096. Pinteraction MI status×sex=0.009.
†Total, n=45 863; women, n=16 038; men, n=29 825. Pinteraction MI status×sex=0.152.
COPD, chronic obstructive pulmonary disease; hs- cTnT, high- sensitivity cardiac troponin T; MI, myocardial infarction; ref cat, reference category.
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DISCUSSION
We evaluated investigations and outcomes of patients admitted to 
a CCU in Sweden with type 1 and type 2 MI, stratified by sex. Our 
study has four main findings. First, while two- thirds of patients 
with type 1 MI were men, the proportion of men and women with 
type 2 MI was identical. Second, although patients with type 2 MI 
were less likely to undergo investigations than those with type 1 
MI, there were no differences in the rates of echocardiography or 
CAG in type 2 MI by sex. More men than women had an impaired 
left ventricular (LV) function and obstructive CAD, and as a conse-
quence women were less likely to undergo revascularisation. Third, 
men and women with type 2 MI were at increased risk of death 
and MACE compared with those with type 1 MI, although these 
differences were attenuated after adjustment for baseline risk and 
comorbidities. Fourth, the prognosis of men with type 2 MI was 
worse than of women, even after adjustment for observed differ-
ences in baseline risk and comorbidities.
Our study has several strengths. The SWEDEHEART registry 
is a large database that consecutively collects data from patients 
with suspected acute coronary syndrome who are admitted to 
CCU in Sweden. This enabled us to gather data on >60 000 
patients with a diagnosis of MI and the largest series of patients 
with type 2 MI reported. The median follow- up of up to 2.8 
years ensured enough outcome events to explore differences in 
determinants of prognosis between men and women.
Our data are in line with findings reported by Neumann et al 
observing similar proportions of men and women among patients 
with type 2 MI.5 Our observations are also consistent with a 
study by McCarthy et al that included 359 patients with type 2 
MI showing that men with type 2 MI had more cardiovascular 
morbidities than their female counterparts.15 Even though men 
from this cohort were younger than women, they presented with 
a greater burden of cardiovascular risk factors. In line with McCa-
rthy et al, we found no differences in echocardiography and CAG 
between men and women, and observed a higher proportion of 
men with impaired LV function and obstructive CAD. McCarthy et 
al reported no difference on 90 days outcome.15 Conversely, in our 
prognostic analysis that included 5442 patients with type 2 MI, we 
showed that men with type 2 MI had worse outcomes as compared 
with women. We believe that this is mostly explained by a greater 
burden of disease among men that increase cardiovascular risk. 
Nonetheless, the contribution of some risk indicators to adverse 
outcome was stronger in women as demonstrated by significant 
interaction terms. This indicates a greater relative importance of 
the absence/presence of these conditions in women compared 
with men. Accordingly, we speculate that men with type 2 MI 
may be more likely to have pre- existent cardiovascular conditions 
contributing to the occurrence of type 2 MI and the associated 
risks, while in women other factors contributing to myocardial 
oxygen supply/demand imbalance may predominate. Raphael et al 
recently showed that underlying mechanism of the supply/demand 
imbalance affects long- term outcome, and further investigation is 
needed to clarify whether the distribution of mechanisms differs 
by sex.16
Both men and women with type 2 MI have a poor prognosis. 
Our study showed that during the follow- up period 50% and 
45% of men and women, respectively, died following type 2 MI. 
Patients with type 2 MI are at increased risk for future MACE 
as compared with patients having type 1 MI.1 2 17 18 In line with 
our previous report,19 the risk of all- cause death and MACE was 
attenuated after adjustment of other risk factors in both men 
and women, suggesting that differences in clinical characteristics 
seem to partly explain the worse outcome in patients with type 
2 MI.
A better understanding of the pathogenic mechanisms respon-
sible for the different outcomes of men and women with type 2 MI 
is urgently needed. Although coronary causes of myocardial oxygen 
supply- demand imbalance in type 2 MI, such as spontaneous coro-
nary dissection, microvascular dysfunction or vasospasm, are less 
common than other cardiac or systemic causes, these conditions 
Figure 3 Sex- specific incidence rates (and their 95% CIs) per 1000 person- years of all- cause death (panel A) and major adverse cardiovascular 
events (MACE) (panel B) for patients with type 1 and type 2 myocardial infarction (MI). MACE is defined as a composite end point of all- cause 
mortality, readmissions for non- fatal MI, heart failure and ischaemic stroke.
Table 4 Risk of all- cause death and major adverse cardiovascular 
events for men and women with type 2 myocardial infarction
HR (95% CI) P value
All- cause death* (men, ref cat)
  Model 1 (crude) 0.82 (0.75 to 0.90) <0.001
  Model 2 (model 1+adjusted for comorbidities) 0.81 (0.74 to 0.90) <0.001
  Model 3 (model 2+adjusted for hs- cTnT concentrations) 0.84 (0.76 to 0.92) ≤0.001
Major adverse cardiovascular events† (men, ref cat)
  Model 1 (crude) 0.87 (0.80 to 0.95) 0.002
  Model 2 (model 1+adjusted for comorbidities) 0.92 (0.84 to 1.01) 0.067
  Model 3 (model 2+adjusted for hs- cTnT concentrations) 0.94 (0.86 to 1.03) 0.189
Model 1: sex, hospital site, year; model 2: model 1+age, current smoking, hypertension, diabetes, hyperlipidaemia, 
coronary artery disease, congestive heart failure, previous stroke, ST- segment depression, estimated glomerular 
filtration rate, COPD, dementia, previous or present cancer; model 3: model 2+hs- cTnT levels.
*Patients with type 2 myocardial infarction, n=4119.
†Patients with type 2 myocardial infarction, n=3979.
COPD, chronic obstructive pulmonary disease; hs- cTnT, high- sensitivity cardiac troponin T; ref cat, reference category.
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are much more frequent in women.20 21 Similarly, there are well- 
established sex differences in type 1 MI where women are more 
likely to have non- obstructive CAD and have better outcomes.22 
A systematic evaluation of the role of CAD in men and women 
with type 2 MI is needed. In those patients with type 2 MI who 
underwent CAG here, obstructive CAD was observed in two- thirds 
of men and one- third of women. Despite this, significantly fewer 
men and women with type 2 MI underwent revascularisation 
compared with those with type 1 MI. This observation is perhaps 
not surprising and is consistent with other reports.23–25 While 
patients with type 2 MI with CAD may benefit from revasculari-
sation, there have been no randomised trials and such therapeutic 
approaches need evaluation in future research. The relationship 
between clinical characteristics and the diagnosis of type 2 MI also 
differed between men and women, with an interaction between 
sex and history of ischaemic stroke and CAD, hyperlipidaemia and 
hs- cTnT. These observations suggest that a sex- specific approach 
to management may be required in type 2 MI.
Several limitations of our analysis merit attention. First, the diag-
nosis of MI was based on discharge coding at the discretion of the 
treating physicians at each hospital. While the SWEDEHEART 
framework recommends the use of criteria outlined in the Universal 
Definition,12 there was no independent adjudication of the diagnosis 
which implies some risk of misclassification. This applies to the MI 
type26 and to other conditions, for example, erroneous coding of 
Takotsubo syndrome as MI, especially during the first years of the 
study period when the awareness of this condition was limited. 
Nonetheless, our approach has the advantage of reflecting clinical 
practice.14 27 Second, no data were available on the cause of type 2 
MI. We lack information on the use of cardiac MRI that may have 
provided clarification in this regard. Third, only peak maximum 
cardiac troponin levels are documented in SWEDEHEART why we 
cannot comment on sampling frequencies or delta changes. Further-
more, we do acknowledge that we may limit generalisability by 
only including patients that were measured by the hs- cTnT assay. 
Fourth, the SWEDEHEART registry is restricted to patients who are 
admitted at CCU in Sweden. Patients with type 2 MI are often also 
admitted outwith the cardiology department, and MI management 
seems to differ with those who are treated at CCU.28 Extrapolating 
our findings to patients with MI managed in other facilities should 
thus be done with caution. Fifth, our composite end point of MACE 
Key messages
What is already known on this subject?
 ► Type 2 myocardial infarction is a heterogenous condition with 
a poor prognosis.
 ► Whether this condition differs in men and women and how 
comorbidities and treatments influence outcome is unknown.
What might this study add?
 ► We report the clinical characteristics, investigations and 
outcomes in a large cohort of consecutive patients admitted 
to a coronary care unit in Sweden with type 1 and type 2 
myocardial infarction, stratified by sex.
 ► Unlike in type 1 myocardial infarction, we observed that type 
2 myocardial infarction occurred in men and women equally, 
and we found no evidence of sex bias in the selection of 
patients for cardiac investigations.
 ► Patients with type 2 myocardial infarction had worse 
outcomes, but women were less likely to have obstructive 
coronary artery disease or severe left ventricular impairment 
and were more likely to survive than men.
How might this impact on clinical practice?
 ► Given the overall poor prognosis, our findings highlight the 
need for meticulous evaluation and close follow- up in men 
and women with type 2 myocardial infarction.
 ► This should include consideration of the need for invasive or 
non- invasive coronary angiography, particularly in men given 
that obstructive disease was identified in two- thirds of those 
selected for testing.
 ► A better understanding of the underlying pathogenic 
mechanisms responsible for different outcomes of men 
and women with type 2 myocardial infarction is urgently 
needed, to inform prospective trials evaluating the potential 
for revascularisation and medical treatments to improve 
outcomes.
Table 5 Associations of clinical characteristics with all- cause death in type 2 myocardial infarction, stratified by sex
Clinical characteristics
All Men Women
Pinteraction with sexHR (95% CI) HR (95% CI) HR (95% CI)
Sex (men, ref cat) 0.83 (0.76 to 0.92)* – – –
Age (per 10 years) 1.82 (1.71 to 1.92)* 1.79 (1.65 to 1.94) 1.87 (1.72 to 2.04) 0.615
Current smoking 1.38 (1.20 to 1.59)* 1.32 (1.09 to 1.60) 1.48 (1.20 to 1.82) 0.359
Hypertension 0.85 (0.77 to 0.93)* 0.87 (0.76 to 0.99) 0.80 (0.69 to 0.93) 0.513
Diabetes 1.28 (1.15 to 1.42)* 1.33 (1.15 to 1.53) 1.26 (1.08 to 1.47) 0.853
Hyperlipidaemia 0.87 (0.78 to 0.96)* 0.84 (0.72 to 0.97) 0.94 (0.81 to 1.10) 0.055†
Coronary artery disease 1.10 (0.99 to 1.22) 0.96 (0.83 to 1.12) 1.26 (1.08 to 1.47) 0.002†
Congestive heart failure 1.60 (1.42 to 1.80)* 1.68 (1.43 to 1.96) 1.51 (1.26 to 1.82) 0.571
Ischaemic stroke 1.44 (1.27 to 1.63)* 1.31 (1.11 to 1.55) 1.58 (1.32 to 1.90) 0.067†
ST- segment depression 1.30 (1.15 to 1.48)* 1.21 (1.02 to 1.44) 1.39 (1.16 to 1.66) 0.677
ln eGFR 0.62 (0.57 to 0.68)* 0.64 (0.57 to 0.72) 0.60 (0.52 to 0.69) 0.250
COPD 1.71 (1.54 to 1.92)* 1.58 (1.35 to 1.85) 1.87 (1.59 to 2.21) 0.143
Dementia 1.53 (1.01 to 2.34)* 1.33 (0.71 to 2.49) 1.61 (0.91 to 2.91) 0.749
Previous cancer 1.45 (1.24 to 1.70)* 1.40 (1.16 to 1.71) 1.61 (1.21 to 2.14) 0.283
ln hs- cTnT 1.14 (1.09 to 1.18)* 1.11 (1.06 to 1.17) 1.18 (1.11 to 1.24) 0.077†
Analyses are adjusted for all assessed variables including hospital and admission year. Pinteraction refers to the interaction of sex with the multivariable- adjusted association of each respective covariate with clinical outcome.
*P<0.05.
†P<0.1.
COPD, chronic obstructive pulmonary disease; ln eGFR, log transformed estimated glomerular filtration rate; ln hs- cTnT, log transformed high- sensitivity cardiac troponin T; ref cat, reference category.
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did not capture re- infarction within 30 days, as the applied registry 
data do not enable us to distinguish a new MI from an index MI 
within that timeframe. Sixth, the majority of patients in the SWEDE-
HEART registry are Caucasian and extending our findings to other 
ethnic groups should be done with caution. Seventh, we did not 
consider patients with STEMI in the primary analysis as care path-
ways for this condition are highly standardised and the majority of 
patients have type 1 MI. Finally, we are unable to comment to which 
extent women with suspected MI are not referred to the CCU, and 
we cannot exclude systemic sex bias in the early management of 
patients with suspected acute coronary syndrome.
In summary, unlike in type 1 MI, we observed that type 2 MI in 
patients admitted to Swedish CCUs occurred in men and women 
equally and we found no evidence of sex bias in the selection of 
patients for cardiac investigation. Patients with type 2 MI had worse 
outcomes even after adjustment for differences in comorbidities, 
but women were less likely to have obstructive CAD or severe LV 
impairment and were more likely to survive than men.
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